Index of drugs

Pre-season and all-year specific immunotherapy of patients with IgE dependent allergy to weed pollen (Catalet C) or trees (Catalet D) or grasses (Catalet T). Immunotherapy with the preparation is recommended in adults and children from 6 years of age.

Catalet C: a mixture of equal amounts of pollen from a mugwort, white louse, plantain and ordinary sorrel. Concentration "1" - 25 JS / ml, concentration "2" - 250 JS / ml, concentration "3" - 2500 JS / ml, concentration "4" - 5000 JS / ml.Catalet D: a mixture of equal amounts of algegoids of alder pollen, birch and common hazel. Concentration "1" - 25 JS / ml, concentration "2" - 250 JS / ml, concentration "3" - 2500 JS / ml, concentration "4" - 5000 JS / ml.Catalet T: a mixture of equal amounts of meadow pollen, pollen, horticulture, common grasshopper, meadow fever, woolly pollen, perennial rye grass, timothy grass, marshmallow and ordinary rye. Concentration "1" - 25 JS / ml, concentration "2" - 250 JS / ml, concentration "3" - 2500 JS / ml, concentration "4" - 10,000 JS / ml.

Vaccines for specific desensitization containing pollen allergens modified with the action of formaldehyde (allergoids), adsorbed on aluminum hydroxide. Immunotherapy is based on the systematic administration of increasing doses of alergoid in order to create a tolerance state for a sensitizing allergen. The mechanism of action is to inhibit the formation of specific IgE antibodies, while stimulating the production of IgG. This leads to alleviation or resolution of clinical symptoms during the natural exposure to the allergen. The proper desensitization effect is obtained after at least 3 cycles (3 years) of immunotherapy.

Hypersensitivity to excipients. acute and chronic inflammation. Severe immunological or immune deficiencies (excluding autoimmune, e.g., type I diabetes mellitus and multiple sclerosis, where the condition of tolerance produced by immunotherapy exerts a beneficial effect by specifically suppressing or disrupting the pathological immune response). Cancers. Severe mental illness. The use of β-blockers (even topically). Poor patient cooperation. Severe asthma resistant to pharmacological treatment and / or irreversible bronchial obstruction (FEV₁ less than 70% of the value due with appropriate pharmacological treatment). Severe cardiovascular diseases that increase the risk of side effects if adrenaline is needed. Insufficiency of internal organs (liver, spleen, kidney, thyroid). Children up to 5 years, except for specific indications.

Only vaccinations that are strictly necessary should be performed during desensitisation. After administration of the preparation, protective vaccination can be performed after one week. After the protective vaccination - the preparation can be used after 2 weeks. The first dose of resumed desensitization should be half as much as the last one tolerated well.

Due to the lack of documented clinical data, the potential risk for the mother and the fetus is unknown. Specific immunotherapy should not be initiated during pregnancy and breast-feeding. If the treatment was started before pregnancy, it can be continued in consultation with the treating physician.

Topical reactions (up to 20 minutes after the injection, late on the day of the injection or on the following days): pruritus, erythema, sometimes edema, rare subcutaneous, itchy bumps (granulomas) that appear 2-3 weeks after the injection. High temperature may occur, eye disorders (burning of the eye), respiratory, thoracic and mediastinal disorders (sneezing, coughing, wheezing, tightness in the chest), skin and subcutaneous tissue disorders (atopic eczema, urticaria, Quincke edema) 'go) and disorders of the immune system (allergic reaction, anaphylactic shock).

Deep subcutaneously, without rubbing the injection site. Indications for desensitisation are determined only by a specialist allergist.The preparation can be used in a preseasonal and all-season scheme.
Scheme of pre-seasonal desensitization. Immunotherapy should be started from the lowest doses used before the pollen season, in the asymptomatic period. Then, by gradually increasing them, a maintenance dose (5000 JS / ml) is achieved for 2 weeks before the pollen season begins. If the maintenance dose is reached much earlier than 2 weeks before the pollen season, it should be repeated every 2 weeks.
Severe allergy symptoms: 0.1 ml concentration "1", then 7 days later 0.5 ml concentration "1", then 7 days later 0.1 ml concentration "2", then 7 days later 0.3 ml concentration "2", then 7 days later, 0.5 ml concentration "2", then 14 days later, 0.1 ml concentration "3", then 7 days later 0.3 ml concentration "3", then 7 days later 0.5 ml concentration "3", then 14 days later 0.2 ml concentration "4", then 7 days later 0.5 ml concentration "4", then 7 days later 1.0 ml concentration "4".Moderate allergy symptoms: 0.5 ml concentration "1", then 7 days later 0.1 ml concentration "2", then 7 days later 0.5 ml concentration "2", then 14 days later 0.1 ml concentration "3", then 7 days later, 0.5 ml concentration "3", then 14 days later 0.2 ml concentration "4", then 7 days later 0.5 ml concentration "4", then 7 days later 1.0 ml concentration "4".Mild allergy symptoms: 0.1 ml concentration "2", then 7 days later 0.5 ml concentration "2", then 14 days later 0.1 ml concentration "3", then 7 days later 0.5 ml concentration "3", then 14 days later 0.2 ml concentration "4", then 7 days later 0.5 ml concentration "4", then 7 days later 1.0 ml concentration "4".
Scheme of year-round treatment. In the first year, treatment should be started according to the pre-season desensitization scheme. In each year of desensitization during the period of pollination, the dose should be reduced in relation to the recently administered, well-tolerated pollen before the season: in the first year immunotherapy up to 20% volume, in the second year immunotherapy up to 30% volume, in the third year immunotherapy up to 40% volume. During pollen period, 4-week intervals between doses should be used. After the pollen season, the dose should be gradually increased at intervals of 1 week, until the full maintenance dose (1 ml) or the highest tolerated dose is reached and immunotherapy continued every 4 weeks until the Next pollen season begins.
Do not exceed the 1 ml dose. Immunotherapy should be carried out for 3-5 years. In the case of desensitization only in the preseasonal regimen in subsequent years, treatment can be started from slightly higher doses than in the previous year. If the break in desensitization is longer than 4 weeks, desensitization should be started from the first dose given.